Latest filing published 18 Sept 2023 for Swedish Orphan Biovitrum, €4.
Filing timeline
BuySaleInsider track record
No signal scores available.
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Norbert Oppitz: trading record in brief
All filings by Norbert Oppitz on record concern Swedish Orphan Biovitrum. Over a trading history stretching from 5 September 2023 to 14 September 2023, the count stands at 2 filings.
Every open-market trade on record is a purchase: 1 purchase worth €4, and no sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket.
The newest entry dates from 18 September 2023: an open-market purchase of €4, in Swedish Orphan Biovitrum. These figures are compiled from regulatory filings published by Finansinspektionen. They describe what insiders did and are not a recommendation.
Companies and markets linked to Norbert Oppitz
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 5 shares@ SEK 10.500.0% of flowTeckningsrätt/UniträttISIN SE0020846285FI:csv-0c18352b93622721c866Canonical exit: 4 Dec 2023 (T+90)
- 4,967 shares@ SEK 142.00100.0% of flowBTA (betald tecknad aktie)ISIN SE0020846293FI:csv-a58c53e7e9076c4c865c
2 of 2 declarations